Inhaled insulin developer Aerami Therapeutics (formerly Dance Biopharm) has announced the appointment of Timm Crowder as Chief Operating Officer. Crowder, who was most recently Chief Operating Officer of Spyryx Biosciences, was a co-founder of DPI developer Oriel Therapeutics. Following Oriel’s acquisition by Sandoz in 2010, Crowder held a series of manufacturing management roles at GSK prior to joining Spyryx in 2015.
In September 2019, Aerami said that it planned to add several inhaled endocrinology therapies to its pipeline in 2020; the company’s lead candidate is the AER 501 insulin soft mist inhaler, which has completed Phase 2 development.
Aerami Therapeutics CEO Anne Whitaker commented, “We are thrilled to have Dr. Crowder join our team as an expert in inhalation technology innovation. Dr. Crowder’s experience developing and executing pharmaceutical operating systems and global manufacturing, will help shape the company’s strategy as we expand our inhaled technology platform beyond diabetes into therapies to treat patients with severe and rare respiratory diseases.”
Crowder said, “As an entrepreneur interested in developing respiratory products for chronic and rare disease, I was encouraged by Aerami Therapeutics’ approach to providing patients with an alternative to routine injections using a platform that delivers aerosol drug formulations as a gentle mist into the lungs. I believe the platform has potential to deliver therapies for a diverse range of chronic diseases. I’m excited to join the management team and look forward to advancing the current pipeline and expanding the pipeline to create long-term value for stakeholders.”
Read the Aerami Therapeutics press release.
